Vitamin K antagonists in heart disease: Current status and perspectives (Section III)
暂无分享,去创建一个
G. Lip | R. de Caterina | C. Baigent | A. Siegbahn | L. Wallentin | J. Morais | K. Huber | F. Verheugt | F. Andreotti | S. Kristensen | H. Arnesen | J. Jespersen | L. Rasmussen | S. Husted | J. Weitz | R. Caterina | F. Bachmann
[1] P. Kirchhof,et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events—European Registry in Atrial Fibrillation (PREFER in AF) , 2013, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[2] G. Lip,et al. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT₂R₂ score. , 2013, Chest.
[3] G. Lip,et al. Comparative assessment of the HAS-BLED score with other published bleeding risk scoring schemes, for intracranial haemorrhage risk in a non-atrial fibrillation population: the Chin-Shan Community Cohort Study. , 2013, International journal of cardiology.
[4] Yutao Guo,et al. Validation of contemporary stroke and bleeding risk stratification scores in non-anticoagulated Chinese patients with atrial fibrillation. , 2013, International journal of cardiology.
[5] S. Connolly,et al. Dabigatran versus warfarin in patients with mechanical heart valves. , 2013, The New England journal of medicine.
[6] G. Lip,et al. Comparative assessment of published atrial fibrillation stroke risk stratification schemes for predicting stroke, in a non-atrial fibrillation population: the Chin-Shan Community Cohort Study. , 2013, International journal of cardiology.
[7] J. Jespersen,et al. Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results: a rebuttal , 2013, Journal of thrombosis and haemostasis : JTH.
[8] R. de Caterina,et al. Parenteral anticoagulants in heart disease: Current status and perspectives (Section II) , 2013, Thrombosis and Haemostasis.
[9] G. Lip,et al. General mechanisms of coagulation and targets of anticoagulants (Section I) , 2013, Thrombosis and Haemostasis.
[10] J. Jespersen,et al. The influence of VKORC1 and CYP2C9 gene sequence variants on the stability of maintenance phase warfarin treatment. , 2013, Thrombosis research.
[11] G. Lip,et al. Performance of the HEMORR 2 HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in nonwarfarin anticoagulated atrial fibrillation patients. , 2013, Journal of the American College of Cardiology.
[12] J. Corral,et al. Creating a genotype-based dosing algorithm for acenocoumarol steady dose , 2012, Thrombosis and Haemostasis.
[13] A. Tripodi,et al. Guidelines for thromboplastins and plasma used to control oral anticoagulant therapy with vitamin K antagonists , 2013 .
[14] G. Lip,et al. Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a "real-world" population with atrial fibrillation receiving anticoagulant therapy. , 2013, Chest.
[15] S. le Cessie,et al. Evaluation of the effect of genetic variations in GATA-4 on the phenprocoumon and acenocoumarol maintenance dose. , 2012, Pharmacogenomics.
[16] Gerhard Hindricks,et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. , 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[17] Jeroen J. Bax,et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. , 2012, European heart journal.
[18] G. Lip,et al. Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm , 2012, Thrombosis and Haemostasis.
[19] E. Butchart,et al. Antithrombotic Management in Patients with Prosthetic Valves , 2012 .
[20] J. Smith,et al. Triple antithrombotic therapy following an acute coronary syndrome: prevalence, outcomes and prognostic utility of the HAS-BLED score. , 2012, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[21] O. Alfieri,et al. Guidelines on the management of valvular heart disease (version 2012). , 2012, European heart journal.
[22] A. Banerjee,et al. Assessing the Risk of Bleeding in Patients With Atrial Fibrillation: The Loire Valley Atrial Fibrillation Project , 2012, Circulation. Arrhythmia and electrophysiology.
[23] O. Alfieri,et al. Guidelines on the management of valvular heart disease. , 2007, European heart journal.
[24] L. Køber,et al. Bleeding After Initiation of Multiple Antithrombotic Drugs, Including Triple Therapy, in Atrial Fibrillation Patients Following Myocardial Infarction and Coronary Intervention: A Nationwide Cohort Study , 2012, Circulation.
[25] Yutao Guo,et al. Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. , 2012, Journal of the American College of Cardiology.
[26] J. Hasenkam,et al. Letter by christensen et Al regarding article, "new oral anticoagulants should not be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation". , 2012, Circulation.
[27] A. Borobia,et al. An Acenocoumarol Dosing Algorithm Using Clinical and Pharmacogenetic Data in Spanish Patients with Thromboembolic Disease , 2012, PloS one.
[28] A. Leppin,et al. Perceived stress predicts the stability of vitamin K-antagonist treatment of anticoagulant clinic patients , 2012, Thrombosis and Haemostasis.
[29] S. Connolly,et al. A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). , 2012, American heart journal.
[30] A. Camm,et al. Efficacy and safety of vernakalant in patients with atrial flutter: a randomized, double-blind, placebo-controlled trial. , 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[31] J. Lindh,et al. A clinically significant interaction between warfarin and simvastatin is unique to carriers of the CYP2C9*3 allele. , 2012, Pharmacogenomics.
[32] Shunichi Homma,et al. Warfarin and aspirin in patients with heart failure and sinus rhythm. , 2012, The New England journal of medicine.
[33] G. Lip,et al. Net Clinical Benefit of Warfarin in Patients With Atrial Fibrillation: A Report From the Swedish Atrial Fibrillation Cohort Study , 2012, Circulation.
[34] An evaluation of gene–gene interaction between the CYP2C9 and VKORC1 genotypes affecting the anticoagulant effect of phenprocoumon and acenocoumarol , 2012, Journal of thrombosis and haemostasis : JTH.
[35] G. Berrut,et al. Pharmacokinetic and Pharmacodynamic Variability of Fluindione in Octogenarians , 2012, Clinical pharmacology and therapeutics.
[36] C. Hammerstingl,et al. The HAS-BLED score predicts bleedings during bridging of chronic oral anticoagulation , 2012, Thrombosis and Haemostasis.
[37] B. Horne,et al. A Randomized and Clinical Effectiveness Trial Comparing Two Pharmacogenetic Algorithms and Standard Care for Individualizing Warfarin Dosing (CoumaGen-II) , 2012, Circulation.
[38] D. Hu,et al. Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients , 2012, Journal of Thrombosis and Thrombolysis.
[39] G. Lip,et al. New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. , 2012, Journal of the American College of Cardiology.
[40] J. Olesen,et al. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0–1: A nationwide cohort study , 2012, Thrombosis and Haemostasis.
[41] S. le Cessie,et al. Long‐term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users , 2012, Journal of thrombosis and haemostasis : JTH.
[42] L. Gourhant,et al. Impact of genetic factors (VKORC1, CYP2C9, CYP4F2 and EPHX1) on the anticoagulation response to fluindione. , 2012, British journal of clinical pharmacology.
[43] Niclas Eriksson,et al. Prediction of warfarin dose: why, when and how? , 2012, Pharmacogenomics.
[44] T. Christensen,et al. Precision and accuracy of point‐of‐care testing coagulometers used for self‐testing and self‐management of oral anticoagulation therapy , 2012, Journal of thrombosis and haemostasis : JTH.
[45] R. Whitlock,et al. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.
[46] Juan Carlos Souto,et al. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data , 2012, The Lancet.
[47] J. Ansell. New oral anticoagulants should not be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation. , 2012, Circulation.
[48] Munir Pirmohamed,et al. Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy , 2011, Thrombosis and Haemostasis.
[49] A. Banerjee,et al. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a ‘real world’ atrial fibrillation population: A modelling analysis based on a nationwide cohort study , 2011, Thrombosis and Haemostasis.
[50] B. Horne,et al. Genotype-Based Dosing Algorithms for Warfarin Therapy , 2011, Molecular Diagnosis & Therapy.
[51] R. de Caterina,et al. Antiplatelet agents for the treatment and prevention of atherothrombosis. , 2011, European heart journal.
[52] M. Levine,et al. Warfarin Dose Assessment Every 4 Weeks Versus Every 12 Weeks in Patients With Stable International Normalized Ratios , 2011, Annals of Internal Medicine.
[53] P. Kirchhof,et al. Bleeding risk assessment and management in atrial fibrillation patients , 2011, Thrombosis and Haemostasis.
[54] B. Horne,et al. Genotype-based dosing algorithms for warfarin therapy: data review and recommendations. , 2011, Molecular diagnosis & therapy.
[55] Deepak L. Bhatt,et al. Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Coronary Stenting: A North American Perspective: Executive Summary , 2011, Circulation. Cardiovascular interventions.
[56] D. Atar,et al. Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.
[57] G. Lip,et al. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: Similarities and dissimilarities between North America and Europe , 2011, Thrombosis and Haemostasis.
[58] G. Breithardt,et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.
[59] P. Weeke,et al. Bleeding risk in ‘real world’ patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort , 2011, Journal of thrombosis and haemostasis : JTH.
[60] J. Tolstrup,et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a ‘real world’ nationwide cohort study , 2011, Thrombosis and Haemostasis.
[61] Lian-Yu Lin,et al. Risk factors and incidence of ischemic stroke in Taiwanese with nonvalvular atrial fibrillation-- a nation wide database analysis. , 2011, Atherosclerosis.
[62] A. Tjønneland,et al. Impact of vascular disease in predicting stroke and death in patients with atrial fibrillation: the Danish Diet, Cancer and Health cohort study , 2011, Journal of thrombosis and haemostasis : JTH.
[63] S. le Cessie,et al. Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. , 2011, European heart journal.
[64] J. Jespersen,et al. Plenty of pills: polypharmacy prevails in patients of a Danish anticoagulant clinic , 2011, European Journal of Clinical Pharmacology.
[65] J. Jespersen,et al. INR derivation with the PT/INR Line simplified using a spreadsheet from the world wide web , 2011, Journal of Clinical Pathology.
[66] J. Tolstrup,et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study , 2011, BMJ : British Medical Journal.
[67] Gregory Y H Lip,et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. , 2011, Journal of the American College of Cardiology.
[68] D. Lane,et al. A comparison of risk stratification schemes for stroke in 79 884 atrial fibrillation patients in general practice , 2011, Journal of thrombosis and haemostasis : JTH.
[69] S. Snowden,et al. Oral Anticoagulation With Warfarin for Patients With Left Ventricular Systolic Dysfunction , 2011, Cardiology in review.
[70] J. Jespersen,et al. The prothrombin time/international normalized ratio (PT/INR) Line: derivation of local INR with commercial thromboplastins and coagulometers – two independent studies , 2011, Journal of thrombosis and haemostasis : JTH.
[71] M. Gold. Effect of Home Testing of International Normalized Ratio on Clinical Events , 2011 .
[72] S. Connolly,et al. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. , 2011, The Canadian journal of cardiology.
[73] Donald R. Lynch. Apixaban in patients with atrial fibrillation. , 2011, The New England journal of medicine.
[74] E. Seifried,et al. Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters , 2010, European Journal of Clinical Pharmacology.
[75] Gregory Y H Lip,et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. , 2010, Chest.
[76] Jeroen J. Bax,et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). , 2010, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[77] J. Jespersen,et al. Simplified method for international normalized ratio (INR) derivation based on the prothrombin time/INR line: an international study. , 2010, Clinical chemistry.
[78] E. Hylek,et al. New-onset atrial fibrillation and warfarin initiation: High risk periods and implications for new antithrombotic drugs , 2010, Thrombosis and Haemostasis.
[79] H. Halkin,et al. Warfarin and vitamin K intake in the era of pharmacogenetics. , 2010, British journal of clinical pharmacology.
[80] P. Kirchhof,et al. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary--a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) a , 2010, European heart journal.
[81] G. Karthikeyan,et al. The CHADS2 score for stroke risk stratification in atrial fibrillation – friend or foe? , 2010, Thrombosis and Haemostasis.
[82] Munir Pirmohamed,et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. , 2010, Blood.
[83] G. Palareti,et al. External quality assessment (EQA) for CoaguChek monitors. , 2010, Thrombosis and haemostasis.
[84] Jenine K. Harris,et al. Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy , 2010, Journal of thrombosis and haemostasis : JTH.
[85] P. Kirchhof,et al. Management of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention/ Stenting , 2009, Thrombosis and Haemostasis.
[86] D. Fitzmaurice,et al. Self-monitoring and self-management of oral anticoagulation. , 2010, The Cochrane database of systematic reviews.
[87] Leon Poller,et al. Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[88] D. Fitzmaurice,et al. Screening computer‐assisted dosage programs for anticoagulation with warfarin and other vitamin K antagonists: minimum safety requirements for individual programs , 2009 .
[89] B. Gersh,et al. New Therapies for Stroke Prevention in Atrial Fibrillation the Long Road to Enhanced Efficacy Article See P 1029 Editorial , 2022 .
[90] M. Ezekowitz,et al. The First Evaluation of a Novel Vitamin K Antagonist, Tecarfarin (ATI-5923), in Patients With Atrial Fibrillation , 2009, Circulation.
[91] Salim Yusuf,et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[92] C. O'connor,et al. Randomized Trial of Warfarin, Aspirin, and Clopidogrel in Patients With Chronic Heart Failure: The Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) Trial , 2009, Circulation.
[93] R. Altman,et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. , 2009, The New England journal of medicine.
[94] L. Poller. Precision and accuracy of CoaguChek S and XS monitors: the need for external quality assessment. , 2009, Thrombosis and haemostasis.
[95] G. Kenet,et al. Activated protein C concentrate treatment for skin necrosis under warfarin treatment in severe genetic protein C deficiency combined with prothrombin mutation and factor V Leiden , 2009, Thrombosis and Haemostasis.
[96] G. Lip,et al. Bleeding risks with combination of oral anticoagulation plus antiplatelet therapy: Is clopidogrel any safer than aspirin when combined with warfarin? , 2008, Thrombosis and Haemostasis.
[97] S Bryan,et al. An international multicenter randomized study of computer‐assisted oral anticoagulant dosage vs. medical staff dosage , 2008, Journal of thrombosis and haemostasis : JTH.
[98] Mark Crowther,et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.
[99] Gregory Y H Lip,et al. Stroke and thromboembolism in atrial fibrillation: A systematic review of stroke risk factors, risk stratification schema and cost effectiveness data , 2008, Thrombosis and Haemostasis.
[100] G. Guyatt,et al. Physicians Evidence-Based Clinical Practice Development : American College of Chest Thrombolytic Therapy Guideline Methodology for Antithrombotic and , 2008 .
[101] A. Vahanian. First European Guidelines on the Management of Valvular Heart Disease , 2007 .
[102] D. Juurlink. Drug interactions with warfarin: what clinicians need to know , 2007, Canadian Medical Association Journal.
[103] G. Lip,et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial , 2007, The Lancet.
[104] Independent predictors of stroke in patients with atrial fibrillation , 2007, Neurology.
[105] M. Aguilar,et al. Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation , 2007, Annals of Internal Medicine.
[106] Pr Alec Vahanian. Guidelines on the management of valvular heart disease: reply , 2007 .
[107] R. de Caterina,et al. Anticoagulants in heart disease: current status and perspectives. , 2007, European heart journal.
[108] H. Halkin,et al. A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. , 2007, Blood.
[109] J. Jespersen,et al. A national field study of quality assessment of CoaguChek point-of-care testing prothrombin time monitors. , 2006, American journal of clinical pathology.
[110] J. Jespersen,et al. Quality assessment of CoaguChek point-of-care prothrombin time monitors: comparison of the European community-approved procedure and conventional external quality assessment. , 2006, Clinical chemistry.
[111] D. Cole,et al. Frequency of CYP2C9 polymorphisms affecting warfarin metabolism in a large anticoagulant clinic cohort. , 2006, Clinical biochemistry.
[112] P. Toutouzas,et al. Efficacy of antithrombotic therapy in chronic heart failure: The HELAS study , 2006, European journal of heart failure.
[113] G. Biondi-Zoccai,et al. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. , 2006, European heart journal.
[114] U. Abildgaard,et al. Gains and losses of warfarin therapy as performed in an anticoagulation clinic , 2006, Journal of internal medicine.
[115] R. Perera,et al. Self-monitoring of oral anticoagulation: a systematic review and meta-analysis , 2006, The Lancet.
[116] Kiyoshi Yoshida,et al. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. , 2006, Stroke.
[117] B. Prendergast,et al. Recommendations for the management of patients after heart valve surgery. , 2005, European heart journal.
[118] Paul D. Martin,et al. Effect of Rosuvastatin on Warfarin Pharmacodynamics and Pharmacokinetics , 2005, Journal of clinical pharmacology.
[119] M. Ufer. Comparative Pharmacokinetics of Vitamin K Antagonists , 2005, Clinical pharmacokinetics.
[120] J. Jespersen,et al. Guidelines on preparation, certification, and use of certified plasmas for ISI calibration and INR determination , 2004, Journal of thrombosis and haemostasis : JTH.
[121] J. Hirsh,et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.
[122] P A Poole-Wilson,et al. The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. , 2004, American heart journal.
[123] L. Poller,et al. International Normalized Ratios (INR): the first 20 years , 2004, Journal of thrombosis and haemostasis : JTH.
[124] J. Herlitza,et al. Effect of fixed low-dose warfarin added to aspirin in the long-term after acute myocardial infarction: the LoWASA study , 2004 .
[125] R. Califf. Watching the WATCH trial: the role of sponsors and data monitoring committees. , 2004, Journal of cardiac failure.
[126] C. O'connor,et al. The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics. , 2004, Journal of cardiac failure.
[127] F. V. D. van der Meer,et al. Patient self‐management of oral anticoagulant care vs. management by specialized anticoagulation clinics: positive effects on quality of life , 2004, Journal of thrombosis and haemostasis : JTH.
[128] J. Jespersen,et al. European concerted action on anticoagulation. Quality assessment of the CoaguChek Mini and TAS PT-NC point-of-care whole-blood prothrombin time monitors. , 2004, Clinical chemistry.
[129] A. Berghold,et al. Systematic review of studies of self-management of oral anticoagulation , 2004, Thrombosis and Haemostasis.
[130] F. Rosendaal,et al. Comparison of the quality of oral anticoagulant therapy through patient self-management and management by specialized anticoagulation clinics in the Netherlands: a randomized clinical trial. , 2003, Archives of internal medicine.
[131] Yuchiao Chang,et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. , 2003, The New England journal of medicine.
[132] Leon Poller,et al. European Concerted Action on Anticoagulation , 2002, Thrombosis and Haemostasis.
[133] V. Kakkar,et al. Blood Coagulation in Patients with Chronic Heart Failure , 2003, Drugs.
[134] G. Lip,et al. Antithrombotic therapy for atrial fibrillation , 2002, BMJ : British Medical Journal.
[135] H. Arnesen,et al. Warfarin, aspirin, or both after myocardial infarction. , 2002, The New England journal of medicine.
[136] G. Uijen,et al. Aspirin Plus Coumarin Versus Aspirin Alone in the Prevention of Reocclusion After Fibrinolysis for Acute Myocardial Infarction: Results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial , 2002, Circulation.
[137] D. Grobbee,et al. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial , 2002, The Lancet.
[138] David L Veenstra,et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. , 2002, JAMA.
[139] M. Ezekowitz,et al. Department of Veterans Affairs Cooperative Studies Program Clinical Trial Comparing Combined Warfarin and Aspirin With Aspirin Alone in Survivors of Acute Myocardial Infarction: Primary Results of the CHAMP Study , 2002, Circulation.
[140] M. Rosenqvist,et al. Management of atrial fibrillation: discrepancy between guideline recommendations and actual practice exposes patients to risk for complications. , 2001, European Heart Journal.
[141] Martha J. Radford,et al. Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation , 2001 .
[142] S. Yusuf,et al. Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina , 2001 .
[143] P. R. R. Ecurrent,et al. EFFECTS OF CLOPIDOGREL IN ADDITION TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION , 2001 .
[144] F. Verheugt,et al. Effect of coumarins started before coronary angioplasty on acute complications and long-term follow-up: a randomized trial. , 2000, Circulation.
[145] B. Hoogwerf,et al. Long-Term Effects on Clinical Outcomes of Aggressive Lowering of Low-Density Lipoprotein Cholesterol Levels and Low-Dose Anticoagulation in the Post Coronary Artery Bypass Graft Trial , 2000 .
[146] L. Frost,et al. Incident stroke after discharge from the hospital with a diagnosis of atrial fibrillation. , 2000, The American journal of medicine.
[147] B. Hoogwerf,et al. Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators. , 2000, Circulation.
[148] R McBride,et al. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. , 1999, Stroke.
[149] T. Lindahl,et al. Influence of Three Types of Automated Coagulometers on the International Sensitivity Index (ISI) of Rabbit, Human, and Recombinant Human Tissue Factor Preparations , 1999, Thrombosis and Haemostasis.
[150] S. Pocock,et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. , 1999, The New England journal of medicine.
[151] S. Pocock,et al. A Clinical Trial Comparing Three Antithrombotic-Drug Regimens after Coronary-Artery Stenting , 1998 .
[152] C. Macaya,et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). , 1998, Circulation.
[153] J. Jespersen,et al. Multicentre randomised study of computerised anticoagulant dosage , 1998, The Lancet.
[154] E. Fleck,et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. , 1998, Circulation.
[155] Y. Ko,et al. Predictors of Systemic Embolism in Patients with Mitral Stenosis: A Prospective Study , 1998, Annals of Internal Medicine.
[156] T. Meade,et al. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk , 1998, The Lancet.
[157] B. Plaud,et al. Population pharmacokinetic‐pharmacodynamic analysis of fluindione in patients , 1998, Clinical pharmacology and therapeutics.
[158] Coumadin Aspirin Reinfarction Study Investigators. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction , 1997, The Lancet.
[159] P. Mannucci,et al. Determination of the International Sensitivity Index of a New Near-Patient Testing Device to Monitor Oral Anticoagulant Therapy , 1997, Thrombosis and Haemostasis.
[160] A. Goguel,et al. Long-term French experience in INR standardization by a procedure using plasma calibrants. , 1997, American journal of clinical pathology.
[161] D. Singer,et al. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. , 1996, The New England journal of medicine.
[162] Vittorio Pengo,et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT) , 1996, The Lancet.
[163] M. Hadamitzky,et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. , 1996, The New England journal of medicine.
[164] David C. Anderson,et al. Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. , 1996, Archives of internal medicine.
[165] A. Colombo,et al. A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. , 1996, Circulation.
[166] M. Ezekowitz,et al. Silent cerebral infarction in patients with nonrheumatic atrial fibrillation. The Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. , 1995, Circulation.
[167] G. Raskob,et al. Hemorrhagic complications of anticoagulant treatment. , 1992, Chest.
[168] Anticoagulants in the Secondary Prevention of Events in Coronary Group. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction , 1994, The Lancet.
[169] R. Kronmal,et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group. , 1994, Circulation.
[170] F R Rosendaal,et al. A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy , 1993, Thrombosis and Haemostasis.
[171] S M Nazarian,et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. , 1992, The New England journal of medicine.
[172] L. Cregler. Antithrombotic therapy in left ventricular thrombosis and systemic embolism. , 1992, American heart journal.
[173] J. Morris,et al. Assessment of value of calibrated lyophilised plasmas to determine International Sensitivity Index for coagulometers. , 1992, Journal of clinical pathology.
[174] R. Falk,et al. Ventricular thrombi and thromboembolism in dilated cardiomyopathy: a prospective follow-up study. , 1992, American heart journal.
[175] M Gent,et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. , 1991, Journal of the American College of Cardiology.
[176] Lippincott Williams Wilkins,et al. Stroke Prevention in Atrial Fibrillation Study: Final Results , 1991, Circulation.
[177] V. Fuster,et al. Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the Antithrombotic Therapy in Acute Coronary Syndromes Study Group). , 1990, The American journal of cardiology.
[178] Bernard Rosner,et al. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. , 1990, The New England journal of medicine.
[179] P Smith,et al. The effect of warfarin on mortality and reinfarction after myocardial infarction. , 1990, The New England journal of medicine.
[180] M. Ray,et al. The Dependence of the International Sensitivity Index on the Coagulometer Used to Perform the Prothrombin Time , 1990, Thrombosis and Haemostasis.
[181] J. Kastrup,et al. Risk factors for thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. , 1990 .
[182] E. van der Velde,et al. The Effect of Some Instruments for Prothrombin Time Testing on the International Sensitivity Index (ISI) of Two Rabbit Tissue Thromboplastin Reagents , 1989, Thrombosis and Haemostasis.
[183] A. Turpie. Prevention of left ventricular mural thrombus. , 1989, The American journal of cardiology.
[184] R. Peters,et al. A Multi-Centre Study to Evaluate Method Dependency of the International Sensitivity Index of Bovine Thromboplastin , 1989, Thrombosis and Haemostasis.
[185] Palle Petersen,et al. PLACEBO-CONTROLLED, RANDOMISED TRIAL OF WARFARIN AND ASPIRIN FOR PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN CHRONIC ATRIAL FIBRILLATION The Copenhagen AFASAK Study , 1989, The Lancet.
[186] J. Stratton,et al. Increased embolic risk in patients with left ventricular thrombi. , 1987, Circulation.
[187] Silvana,et al. Relationship between protein C antigen and anticoagulant activity during oral anticoagulation and in selected disease states. , 1986, The Journal of clinical investigation.
[188] J. Soria,et al. Successful Progressive Anticoagulation in a Severe Protein C Deficiency and Previous Skin Necrosis at the Initiation of Oral Anticoagulant Treatment , 1984, Thrombosis and Haemostasis.
[189] T B Kirkwood,et al. Calibration of Reference Thromboplastins and Standardisation of the Prothrombin Time Ratio , 1983, Thrombosis and Haemostasis.
[190] P. Szekely. Systemic Embolism and Anticoagulant Prophylaxis in Rheumatic Heart Disease , 1964, British medical journal.
[191] K. P. Link,et al. Studies on the Hemorrhagic Sweet Clover Disease IX. The Effect of Diet and Vitamin K on the Hypopro-Thrombinemia Induced by 3,3???-Methylenebis (4-Hydroxycoumarin) in the RatOne Figure , 1942 .